Merck Gains Phase II SARM For Muscle Loss With GTx Deal
Merck, GTx pool their selective androgen receptor modulator programs in a deal valued at over $500 million.
Merck, GTx pool their selective androgen receptor modulator programs in a deal valued at over $500 million.